Abstract
This chapter is meant to present readers with detailed accounts of studies that have used either directly labeled or indirectly labeled activated T cells to gain insights into the complex nature of cancer immunotherapy (CIT). The goal of CIT is to achieve specific tumor cell eradication while imposing minimal systemic toxicity. Yet, the high cost of CIT and the challenges associated with patient stratification present clinicians with significant hurdles. The use of combined CITs further elevates the level of complexity of these cellular interactions. The complex nature of CIT, thus, demands a clear understanding of how immune cell functions and migration patterns relate to treatment effectiveness. The goal of T cell tracking investigations, therefore, is to provide accurate insights for linking migration patterns of activated T cells to clinical therapeutic outcomes. Moreover, accurate assessments of T cell migration and function during the course of CIT may allow clinicians to develop methods for stratifying patient populations and selecting ideal treatments.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Miller JF, Sadelain M. The journey from discoveries in fundamental immunology to cancer immunotherapy. Cancer Cell. 2015;27(4):439–49. https://doi.org/10.1016/j.ccell.2015.03.007.
Ayed AO, Chang LJ, Moreb JS. Immunotherapy for multiple myeloma: current status and future directions. Crit Rev Oncol Hematol. 2015;96(3):399–412. https://doi.org/10.1016/j.critrevonc.2015.06.006.
Littman DR. Releasing the brakes on cancer immunotherapy. Cell. 2015;162(6):1186–90. https://doi.org/10.1016/j.cell.2015.08.038.
Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161(2):205–14. https://doi.org/10.1016/j.cell.2015.03.030.
Palucka AK, Coussens LM. The basis of oncoimmunology. Cell. 2016;164(6):1233–47. https://doi.org/10.1016/j.cell.2016.01.049.
Emens LA, Ascierto PA, Darcy PK, Demaria S, Eggermont AMM, Redmond WL, et al. Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape. Eur J Cancer. 2017;81:116–29. https://doi.org/10.1016/j.ejca.2017.01.035.
Jung SH, Lee HJ, Vo MC, Kim HJ, Lee JJ. Immunotherapy for the treatment of multiple myeloma. Crit Rev Oncol Hematol. 2017;111:87–93. https://doi.org/10.1016/j.critrevonc.2017.01.011.
Rasche L, Weinhold N, Morgan GJ, van Rhee F, Davies FE. Immunologic approaches for the treatment of multiple myeloma. Cancer Treat Rev. 2017;55:190–9. https://doi.org/10.1016/j.ctrv.2017.03.010.
Franchina DG, Dostert C, Brenner D. Reactive oxygen species: involvement in T cell signaling and metabolism. Trends Immunol. 2018;39(6):489–502. https://doi.org/10.1016/j.it.2018.01.005.
Spitzer MH, Carmi Y, Reticker-Flynn NE, Kwek SS, Madhireddy D, Martins MM, et al. Systemic immunity is required for effective cancer immunotherapy. Cell. 2017;168(3):487–502.e15. https://doi.org/10.1016/j.cell.2016.12.022.
Madden DL. From a patient advocate’s perspective: does cancer immunotherapy represent a paradigm shift? Curr Oncol Rep. 2018;20(1):8. https://doi.org/10.1007/s11912-018-0662-5.
Tang J, Shalabi A, Hubbard-Lucey VM. Comprehensive analysis of the clinical immuno-oncology landscape. Ann Oncol. 2018;29(1):84–91. https://doi.org/10.1093/annonc/mdx755.
Danhof S, Hudecek M, Smith EL. CARs and other T cell therapies for MM: the clinical experience. Best Pract Res Clin Haematol. 2018;31(2):147–57. https://doi.org/10.1016/j.beha.2018.03.002.
Suck G, Koh MBC. Emerging natural killer cell immunotherapies: large-scale ex vivo production of highly potent anticancer effectors. Hematol Oncol Stem Cell Ther. 2010;3(3):135–42.
Granzin M, Soltenborn S, Muller S, Kollet J, Berg M, Cerwenka A, et al. Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy. Cytotherapy. 2015;17(5):621–32. https://doi.org/10.1016/j.jcyt.2015.03.611.
Fang F, Xiao W, Tian Z. NK cell-based immunotherapy for cancer. Semin Immunol. 2017;31:37–54. https://doi.org/10.1016/j.smim.2017.07.009.
Malmberg KJ, Carlsten M, Bjorklund A, Sohlberg E, Bryceson YT, Ljunggren HG. Natural killer cell-mediated immunosurveillance of human cancer. Semin Immunol. 2017;31:20–9. https://doi.org/10.1016/j.smim.2017.08.002.
Lin C, Zhang J. Reformation in chimeric antigen receptor based cancer immunotherapy: redirecting natural killer cell. Biochim Biophys Acta Rev Cancer. 2018;1869(2):200–15. https://doi.org/10.1016/j.bbcan.2018.01.005.
Daher M, Rezvani K. Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. Curr Opin Immunol. 2018;51:146–53. https://doi.org/10.1016/j.coi.2018.03.013.
Andón FT, Digifico E, Maeda A, Erreni M, Mantovani A, Alonso MJ, et al., editors. Targeting tumor associated macrophages: the new challenge for nanomedicine, Seminars in immunology. Amsterdam: Elsevier; 2017.
Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298(5594):850–4.
Park TS, Rosenberg SA, Morgan RA. Treating cancer with genetically engineered T cells. Trends Biotechnol. 2011;29(11):550–7. https://doi.org/10.1016/j.tibtech.2011.04.009.
Wang M, Yin B, Wang HY, Wang R-F. Current advances in T-cell-based cancer immunotherapy. Immunotherapy. 2014;6(12):1265–78.
Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. 2011;19(3):620–6. https://doi.org/10.1038/mt.2010.272.
Wu CY, Rupp LJ, Roybal KT, Lim WA. Synthetic biology approaches to engineer T cells. Curr Opin Immunol. 2015;35:123–30. https://doi.org/10.1016/j.coi.2015.06.015.
Klebanoff CA, Restifo NP. Customizing functionality and payload delivery for receptor-engineered T cells. Cell. 2016;167(2):304–6. https://doi.org/10.1016/j.cell.2016.09.033.
Johnson LA, June CH. Driving gene-engineered T cell immunotherapy of cancer. Cell Res. 2017;27(1):38–58. https://doi.org/10.1038/cr.2016.154.
Yee C. Adoptive T cell therapy: points to consider. Curr Opin Immunol. 2018;51:197–203. https://doi.org/10.1016/j.coi.2018.04.007.
Tyler CJ, Doherty DG, Moser B, Eberl M. Human Vgamma9/Vdelta2 T cells: innate adaptors of the immune system. Cell Immunol. 2015;296(1):10–21. https://doi.org/10.1016/j.cellimm.2015.01.008.
Chitadze G, Oberg H-H, Wesch D, Kabelitz D. The ambiguous role of γδ T lymphocytes in antitumor immunity. Trends Immunol. 2017;38(9):668–78.
Kabelitz D. Human γδ T cells: from a neglected lymphocyte population to cellular immunotherapy: a personal reflection of 30 years of γδ T cell research. Clin Immunol. 2016;100(172):90–7.
Allegra A, Innao V, Gerace D, Vaddinelli D, Musolino C. Adoptive immunotherapy for hematological malignancies: current status and new insights in chimeric antigen receptor T cells. Blood Cells Mol Dis. 2016;62:49–63. https://doi.org/10.1016/j.bcmd.2016.11.001.
Blidner AG, Marino KV, Rabinovich GA. Driving CARs into sweet roads: targeting glycosylated antigens in cancer. Immunity. 2016;44(6):1248–50. https://doi.org/10.1016/j.immuni.2016.06.010.
Brown CE, Adusumilli PS. Next frontiers in CAR T-cell therapy. Mol Ther Oncolytics. 2016;3:16028. https://doi.org/10.1038/mto.2016.28.
Fesnak A, Lin C, Siegel DL, Maus MV. CAR-T cell therapies from the transfusion medicine perspective. Transfus Med Rev. 2016;30(3):139–45. https://doi.org/10.1016/j.tmrv.2016.03.001.
Gad AZ, El-Naggar S, Ahmed N. Realism and pragmatism in developing an effective chimeric antigen receptor T-cell product for solid cancers. Cytotherapy. 2016;18(11):1382–92. https://doi.org/10.1016/j.jcyt.2016.07.004.
Geyer MB, Brentjens RJ. Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells. Cytotherapy. 2016;18(11):1393–409. https://doi.org/10.1016/j.jcyt.2016.07.003.
Gill S, Maus MV, Porter DL. Chimeric antigen receptor T cell therapy: 25 years in the making. Blood Rev. 2016;30(3):157–67. https://doi.org/10.1016/j.blre.2015.10.003.
Newick K, Moon E, Albelda SM. Chimeric antigen receptor T-cell therapy for solid tumors. Mol Ther Oncolytics. 2016;3:16006. https://doi.org/10.1038/mto.2016.6.
Sadelain M. Chimeric antigen receptors: driving immunology towards synthetic biology. Curr Opin Immunol. 2016;41:68–76. https://doi.org/10.1016/j.coi.2016.06.004.
Smith AJ, Oertle J, Warren D, Prato D. Chimeric antigen receptor (CAR) T cell therapy for malignant cancers: summary and perspective. J Cell Immunother. 2016;2(2):59–68. https://doi.org/10.1016/j.jocit.2016.08.001.
Wang X, Riviere I. Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncolytics. 2016;3:16015. https://doi.org/10.1038/mto.2016.15.
Bollino D, Webb TJ. Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy. Transl Res. 2017;187:32–43. https://doi.org/10.1016/j.trsl.2017.06.003.
Chang ZL, Chen YY. CARs: synthetic immunoreceptors for cancer therapy and beyond. Trends Mol Med. 2017;23(5):430–50. https://doi.org/10.1016/j.molmed.2017.03.002.
de Wilde S, Guchelaar HJ, Zandvliet ML, Meij P. Understanding clinical development of chimeric antigen receptor T cell therapies. Cytotherapy. 2017;19(6):703–9. https://doi.org/10.1016/j.jcyt.2017.03.070.
Frey N. The what, when and how of CAR T cell therapy for ALL. Best Pract Res Clin Haematol. 2017;30(3):275–81. https://doi.org/10.1016/j.beha.2017.07.009.
Han S, Latchoumanin O, Wu G, Zhou G, Hebbard L, George J, et al. Recent clinical trials utilizing chimeric antigen receptor T cells therapies against solid tumors. Cancer Lett. 2017;390:188–200. https://doi.org/10.1016/j.canlet.2016.12.037.
Jaspers JE, Brentjens RJ. Development of CAR T cells designed to improve antitumor efficacy and safety. Pharmacol Ther. 2017;178:83–91. https://doi.org/10.1016/j.pharmthera.2017.03.012.
Lim WA, June CH. The principles of engineering immune cells to treat cancer. Cell. 2017;168(4):724–40. https://doi.org/10.1016/j.cell.2017.01.016.
Riviere I, Sadelain M. Chimeric antigen receptors: a cell and gene therapy perspective. Mol Ther. 2017;25(5):1117–24. https://doi.org/10.1016/j.ymthe.2017.03.034.
Kenderian SS, Porter DL, Gill S. Chimeric antigen receptor T cells and hematopoietic cell transplantation: how not to put the CART before the horse. Biol Blood Marrow Transplant. 2017;23(2):235–46. https://doi.org/10.1016/j.bbmt.2016.09.002.
Zheng PP, Kros JM, Li J. Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts. Drug Discov Today. 2018;23(6):1175–82. https://doi.org/10.1016/j.drudis.2018.02.012.
Si W, Li C, Wei P. Synthetic immunology: T-cell engineering and adoptive immunotherapy. Synth Syst Biotechnol. 2018;3(3):179–85. https://doi.org/10.1016/j.synbio.2018.08.001.
Siddiqi HF, Staser KW, Nambudiri VE. Research techniques made simple: CAR T-cell therapy. J Invest Dermatol. 2018;138(12):2501–4.e1. https://doi.org/10.1016/j.jid.2018.09.002.
Ramello MC, Haura EB, Abate-Daga D. CAR-T cells and combination therapies: what’s next in the immunotherapy revolution? Pharmacol Res. 2018;129:194–203. https://doi.org/10.1016/j.phrs.2017.11.035.
Grupp S. Beginning the CAR T cell therapy revolution in the US and EU. Curr Res Transl Med. 2018;66(2):62–4. https://doi.org/10.1016/j.retram.2018.03.004.
Halim L, Ajina A, Maher J. Pre-clinical development of chimeric antigen receptor T-cell immunotherapy: implications of design for efficacy and safety. Best Pract Res Clin Haematol. 2018;31(2):117–25. https://doi.org/10.1016/j.beha.2018.04.002.
Calmels B, Mfarrej B, Chabannon C. From clinical proof-of-concept to commercialization of CAR T cells. Drug Discov Today. 2018;23(4):758–62. https://doi.org/10.1016/j.drudis.2018.01.024.
Chen N, Li X, Chintala NK, Tano ZE, Adusumilli PS. Driving CARs on the uneven road of antigen heterogeneity in solid tumors. Curr Opin Immunol. 2018;51:103–10. https://doi.org/10.1016/j.coi.2018.03.002.
Minn AJ, Wherry EJ. Combination cancer therapies with immune checkpoint blockade: convergence on interferon signaling. Cell. 2016;165(2):272–5. https://doi.org/10.1016/j.cell.2016.03.031.
Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016;17(12):e542–e51. https://doi.org/10.1016/s1470-2045(16)30406-5.
Gay F, D’Agostino M, Giaccone L, Genuardi M, Festuccia M, Boccadoro M, et al. Immuno-oncologic approaches: CAR-T cells and checkpoint inhibitors. Clin Lymphoma Myeloma Leuk. 2017;17(8):471–8. https://doi.org/10.1016/j.clml.2017.06.014.
Shao J, Xu Q, Su S, Meng F, Zou Z, Chen F, et al. Engineered cells for costimulatory enhancement combined with IL-21 enhance the generation of PD-1-disrupted CTLs for adoptive immunotherapy. Cell Immunol. 2017;320:38–45. https://doi.org/10.1016/j.cellimm.2017.09.003.
Jacobson CA, Armand P. Immunotherapy in aggressive B-cell lymphomas. Best Pract Res Clin Haematol. 2018;31(3):299–305. https://doi.org/10.1016/j.beha.2018.07.015.
Roybal KT, Rupp LJ, Morsut L, Walker WJ, McNally KA, Park JS, et al. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell. 2016;164(4):770–9. https://doi.org/10.1016/j.cell.2016.01.011.
Themeli M, Sadelain M. Combinatorial antigen targeting: ideal T-cell sensing and anti-tumor response. Trends Mol Med. 2016;22(4):271–3. https://doi.org/10.1016/j.molmed.2016.02.009.
Biggs MJ, Milone MC, Santos LC, Gondarenko A, Wind SJ. High-resolution imaging of the immunological synapse and T-cell receptor microclustering through microfabricated substrates. J R Soc Interface. 2011;8(63):1462–71. https://doi.org/10.1098/rsif.2011.0025.
Illingworth JJ, Anton van der Merwe P. Dissecting T-cell activation with high-resolution live-cell microscopy. Immunology. 2012;135(3):198–206. https://doi.org/10.1111/j.1365-2567.2011.03537.x.
Neve-Oz Y, Razvag Y, Sajman J, Sherman E. Mechanisms of localized activation of the T cell antigen receptor inside clusters. Biochim Biophys Acta. 2015;1853(4):810–21. https://doi.org/10.1016/j.bbamcr.2014.09.025.
Chang CH, Qiu J, O’Sullivan D, Buck MD, Noguchi T, Curtis JD, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell. 2015;162(6):1229–41. https://doi.org/10.1016/j.cell.2015.08.016.
Zitvogel L, Ayyoub M, Routy B, Kroemer G. Microbiome and anticancer immunosurveillance. Cell. 2016;165(2):276–87. https://doi.org/10.1016/j.cell.2016.03.001.
Hu KH, Butte MJ. T cell activation requires force generation. J Cell Biol. 2016;213(5):535–42. https://doi.org/10.1083/jcb.201511053.
Le Borgne M, Raju S, Zinselmeyer BH, Le VT, Li J, Wang Y, et al. Real-time analysis of calcium signals during the early phase of T cell activation using a genetically encoded calcium biosensor. J Immunol. 2016;196(4):1471–9.
Sathappan A, van Panhuys N. Advances in in vivo imaging techniques for the visualization and quantification of DC-T cell interactions. J Immunobiol. 2017;2:2. https://doi.org/10.4172/2476-1966.1000125.
Stein JV, Gonzalez SF. Dynamic intravital imaging of cell-cell interactions in the lymph node. J Allergy Clin Immunol. 2017;139(1):12–20.
Beaurepaire E, Pavone FS, So PTC, Gavgiotaki E, Filippidis G, Zerva I, et al. Nonlinear microscopy as diagnostic tool for the discrimination of activated T cells. Adv Microsc Imaging. 2017; https://doi.org/10.1117/12.2282895.
Andrejeva G, Rathmell JC. Similarities and distinctions of cancer and immune metabolism in inflammation and tumors. Cell Metab. 2017;26(1):49–70. https://doi.org/10.1016/j.cmet.2017.06.004.
Mukherjee M, Mace EM, Carisey AF, Ahmed N, Orange JS. Quantitative imaging approaches to study the CAR immunological synapse. Mol Ther. 2017;25(8):1757–68. https://doi.org/10.1016/j.ymthe.2017.06.003.
Beckermann KE, Dudzinski SO, Rathmell JC. Dysfunctional T cell metabolism in the tumor microenvironment. Cytokine Growth Factor Rev. 2017;35:7–14. https://doi.org/10.1016/j.cytogfr.2017.04.003.
Dugnani E, Pasquale V, Bordignon C, Canu A, Piemonti L, Monti P. Integrating T cell metabolism in cancer immunotherapy. Cancer Lett. 2017;411:12–8. https://doi.org/10.1016/j.canlet.2017.09.039.
Ho P-C, Kaech SM. Reenergizing T cell anti-tumor immunity by harnessing immunometabolic checkpoints and machineries. Curr Opin Immunol. 2017;46:38–44.
Kishton RJ, Sukumar M, Restifo NP. Metabolic regulation of T cell longevity and function in tumor immunotherapy. Cell Metab. 2017;26(1):94–109. https://doi.org/10.1016/j.cmet.2017.06.016.
Hardaway JC, Prince E, Arepally A, Katz SC. Regional infusion of chimeric antigen receptor T cells to overcome barriers for solid tumor immunotherapy. J Vasc Intervent Radiol. 2018;29(7):1017–21.e1.
Xiong W, Chen Y, Kang X, Chen Z, Zheng P, Hsu YH, et al. Immunological synapse predicts effectiveness of chimeric antigen receptor cells. Mol Ther. 2018;26(4):963–75. https://doi.org/10.1016/j.ymthe.2018.01.020.
Zhang L, Romero P. Metabolic control of CD8+ T cell fate decisions and antitumor immunity. Trends Mol Med. 2018;24(1):30–48.
Moogk D, Natarajan A, Krogsgaard M. T cell receptor signal transduction: affinity, force and conformational change. Curr Opin Chem Eng. 2018;19:43–50. https://doi.org/10.1016/j.coche.2017.12.007.
Sukumar M, Kishton RJ, Restifo NP. Metabolic reprograming of anti-tumor immunity. Curr Opin Immunol. 2017;46:14–22.
Yang QY, Yang JD, Wang YS. Current strategies to improve the safety of chimeric antigen receptor (CAR) modified T cells. Immunol Lett. 2017;190:201–5. https://doi.org/10.1016/j.imlet.2017.08.018.
Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbe C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412–20. https://doi.org/10.1158/1078-0432.CCR-09-1624.
Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ. Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics. 2016;3:16011. https://doi.org/10.1038/mto.2016.11.
Pitt JM, Vetizou M, Daillere R, Roberti MP, Yamazaki T, Routy B, et al. Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors. Immunity. 2016;44(6):1255–69. https://doi.org/10.1016/j.immuni.2016.06.001.
Frey N. Cytokine release syndrome: who is at risk and how to treat. Best Pract Res Clin Haematol. 2017;30(4):336–40. https://doi.org/10.1016/j.beha.2017.09.002.
Kim S, Moon EK. Development of novel avenues to overcome challenges facing CAR T cells. Transl Res. 2017;187:22–31. https://doi.org/10.1016/j.trsl.2017.05.009.
Perales MA, Kebriaei P, Kean LS, Sadelain M. Building a safer and faster CAR: seatbelts, airbags, and CRISPR. Biol Blood Marrow Transplant. 2018;24(1):27–31. https://doi.org/10.1016/j.bbmt.2017.10.017.
Gauthier J, Yakoub-Agha I. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: clinical data to date, current limitations and perspectives. Curr Res Transl Med. 2017;65(3):93–102. https://doi.org/10.1016/j.retram.2017.08.003.
Bailly C, Clery PF, Faivre-Chauvet A, Bourgeois M, Guerard F, Haddad F, et al. Immuno-PET for clinical theranostic approaches. Int J Mol Sci. 2016;18(1):57. https://doi.org/10.3390/ijms18010057.
Wu C, Ma G, Li J, Zheng K, Dang Y, Shi X, et al. In vivo cell tracking via (1)(8)F-fluorodeoxyglucose labeling: a review of the preclinical and clinical applications in cell-based diagnosis and therapy. Clin Imaging. 2013;37(1):28–36. https://doi.org/10.1016/j.clinimag.2012.02.023.
Tirumani SH, Ramaiya NH, Keraliya A, Bailey ND, Ott PA, Hodi FS, et al. Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res. 2015;3(10):1185–92.
Kong BY, Menzies AM, Saunders CA, Liniker E, Ramanujam S, Guminski A, et al. Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy. Pigment Cell Melanoma Res. 2016;29(5):572–7. https://doi.org/10.1111/pcmr.12503.
Cottereau AS, Becker S, Broussais F, Casasnovas O, Kanoun S, Roques M, et al. Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL). Ann Oncol. 2016;27(4):719–24. https://doi.org/10.1093/annonc/mdw011.
Cho SY, Lipson EJ, Im HJ, Rowe SP, Gonzalez EM, Blackford A, et al. Prediction of response to immune checkpoint inhibitor therapy using early-time-point (18)F-FDG PET/CT imaging in patients with advanced melanoma. J Nucl Med. 2017;58(9):1421–8. https://doi.org/10.2967/jnumed.116.188839.
Shah NN, Nagle SJ, Torigian DA, Farwell MD, Hwang WT, Frey N, et al. Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor-T-cell therapy in B-cell non-Hodgkin lymphomas. Cytotherapy. 2018;20(12):1415–8. https://doi.org/10.1016/j.jcyt.2018.10.003.
Mekki A, Dercle L, Lichtenstein P, Marabelle A, Michot J-M, Lambotte O, et al. Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1. Eur J Cancer. 2018;96:91–104.
Wang J, Hu Y, Yang S, Wei G, Zhao X, Wu W, et al. Role of fluorodeoxyglucose positron emission tomography/computed tomography in predicting the adverse effects of chimeric antigen receptor T cell therapy in patients with non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2019;25(6):1092–8. https://doi.org/10.1016/j.bbmt.2019.02.008.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.
Bauckneht M, Piva R, Sambuceti G, Grossi F, Morbelli S. Evaluation of response to immune checkpoint inhibitors: is there a role for positron emission tomography? World J Radiol. 2017;9(2):27–33. https://doi.org/10.4329/wjr.v9.i2.27.
Evangelista L, de Jong M, Del Vecchio S, Cai W. The new era of cancer immunotherapy: what can molecular imaging do to help? Clin Transl Imaging. 2017;5(4):299–301. https://doi.org/10.1007/s40336-017-0241-z.
Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol. 2016;34(13):1510–7. https://doi.org/10.1200/JCO.2015.64.0391.
Hildebrandt IJ, Gambhir SS. Molecular imaging applications for immunology. Clin Immunol. 2004;111(2):210–24. https://doi.org/10.1016/j.clim.2003.12.018.
Skitzki JJ, Muhitch JB, Evans SS. Tracking the elusive lymphocyte: methods of detection during adoptive immunotherapy. Immunol Investig. 2007;36(5–6):807–27. https://doi.org/10.1080/08820130701712867.
Nair-Gill E, Wiltzius SM, Wei XX, Cheng D, Riedinger M, Radu CG, et al. PET probes for distinct metabolic pathways have different cell specificities during immune responses in mice. J Clin Invest. 2010;120(6):2005–15. https://doi.org/10.1172/JCI41250.
Srinivas M, Aarntzen EH, Bulte JW, Oyen WJ, Heerschap A, de Vries IJ, et al. Imaging of cellular therapies. Adv Drug Deliv Rev. 2010;62(11):1080–93. https://doi.org/10.1016/j.addr.2010.08.009.
Kircher MF, Gambhir SS, Grimm J. Noninvasive cell-tracking methods. Nat Rev Clin Oncol. 2011;8(11):677–88. https://doi.org/10.1038/nrclinonc.2011.141.
Ottobrini L, Martelli C, Trabattoni DL, Clerici M, Lucignani G. In vivo imaging of immune cell trafficking in cancer. Eur J Nucl Med Mol Imaging. 2011;38(5):949–68. https://doi.org/10.1007/s00259-010-1687-7.
Youn H, Hong KJ. In vivo non invasive molecular imaging for immune cell tracking in small animals. Immune Netw. 2012;12(6):223–9. https://doi.org/10.4110/in.2012.12.6.223.
Leech JM, Sharif-Paghaleh E, Maher J, Livieratos L, Lechler RI, Mullen GE, et al. Whole-body imaging of adoptively transferred T cells using magnetic resonance imaging, single photon emission computed tomography and positron emission tomography techniques, with a focus on regulatory T cells. Clin Exp Immunol. 2013;172(2):169–77. https://doi.org/10.1111/cei.12087.
Srinivas M, Melero I, Kaempgen E, Figdor CG, de Vries IJ. Cell tracking using multimodal imaging. Contrast Media Mol Imaging. 2013;8(6):432–8. https://doi.org/10.1002/cmmi.1561.
Liu Z, Li Z. Molecular imaging in tracking tumor-specific cytotoxic T lymphocytes (CTLs). Theranostics. 2014;4(10):990.
Neri D. Imaging T cells in vivo. J Nucl Med. 2015;56(8):1135–6. https://doi.org/10.2967/jnumed.115.159533.
Lee HW, Gangadaran P, Kalimuthu S, Ahn BC. Advances in molecular imaging strategies for in vivo tracking of immune cells. Biomed Res Int. 2016;2016:1946585. https://doi.org/10.1155/2016/1946585.
Hartimath SV, Draghiciu O, van de Wall S, Manuelli V, Dierckx RA, Nijman HW, et al. Noninvasive monitoring of cancer therapy induced activated T cells using [(18)F]FB-IL-2 PET imaging. Oncoimmunology. 2017;6(1):e1248014. https://doi.org/10.1080/2162402X.2016.1248014.
Du Y, Jin Y, Sun W, Fang J, Zheng J, Tian J. Advances in molecular imaging of immune checkpoint targets in malignancies: current and future prospect. Eur Radiol. 2019;29(8):4294–302. https://doi.org/10.1007/s00330-018-5814-3.
Wei W, Jiang D, Ehlerding EB, Luo Q, Cai W. Noninvasive PET imaging of T cells. Trends Cancer. 2018;4(5):359–73. https://doi.org/10.1016/j.trecan.2018.03.009.
Zeelen C, Paus C, Draper D, Heskamp S, Signore A, Galli F, et al. In-vivo imaging of tumor-infiltrating immune cells: implications for cancer immunotherapy. Q J Nucl Med Mol Imaging. 2018;62(1):56–77. https://doi.org/10.23736/S1824-4785.17.03052-7.
Mayer AT, Gambhir SS. The immunoimaging toolbox. J Nucl Med. 2018;59(8):1174–82. https://doi.org/10.2967/jnumed.116.185967.
Emami-Shahri N, Foster J, Kashani R, Gazinska P, Cook C, Sosabowski J, et al. Clinically compliant spatial and temporal imaging of chimeric antigen receptor T-cells. Nat Commun. 2018;9(1):1081. https://doi.org/10.1038/s41467-018-03524-1.
Adams CL, Rush CM, Smith KM, Garside P. Tracking antigen-specific lymphocytes in vivo. In: D’Ambrosio D, Sinigaglia F, editors. Cell migration in inflammation and immunity: methods and protocols. Totowa, NJ: Humana Press; 2003. p. 133–46.
Diken M, Pektor S, Miederer M. Harnessing the potential of noninvasive in vivo preclinical imaging of the immune system: challenges and prospects. Nanomedicine. 2016;11(20):2711–22.
Hong H, Yang Y, Zhang Y, Cai W. Non-invasive cell tracking in cancer and cancer therapy. Curr Top Med Chem. 2010;10(12):1237–48.
Singh A, Radu C, Ribas A. PET imaging of the immune system: immune monitoring at the whole body level. Q J Nucl Med Mol Imaging. 2010;54(3):281–90.
Bulte JW. In vivo MRI cell tracking: clinical studies. AJR Am J Roentgenol. 2009;193(2):314–25. https://doi.org/10.2214/AJR.09.3107.
Himmelreich U, Dresselaers T. Cell labeling and tracking for experimental models using magnetic resonance imaging. Methods. 2009;48(2):112–24. https://doi.org/10.1016/j.ymeth.2009.03.020.
Ahrens ET, Bulte JW. Tracking immune cells in vivo using magnetic resonance imaging. Nat Rev Immunol. 2013;13(10):755–63. https://doi.org/10.1038/nri3531.
Seth A, Park HS, Hong KS. Current perspective on in vivo molecular imaging of immune cells. Molecules. 2017;22(6):881. https://doi.org/10.3390/molecules22060881.
Chapelin F, Capitini CM, Ahrens ET. Fluorine-19 MRI for detection and quantification of immune cell therapy for cancer. J Immunother Cancer. 2018;6(1):105.
Beckmann N, Cannet C, Babin AL, Blé FX, Zurbruegg S, Kneuer R, et al. In vivo visualization of macrophage infiltration and activity in inflammation using magnetic resonance imaging. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009;1(3):272–98.
Wang Y, Xu C, Ow H. Commercial nanoparticles for stem cell labeling and tracking. Theranostics. 2013;3(8):544–60. https://doi.org/10.7150/thno.5634.
Weissleder R, Nahrendorf M, Pittet MJ. Imaging macrophages with nanoparticles. Nat Mater. 2014;13(2):125–38. https://doi.org/10.1038/nmat3780.
Meir R, Popovtzer R. Cell tracking using gold nanoparticles and computed tomography imaging. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2018;10(2):28544497. https://doi.org/10.1002/wnan.1480.
Meir R, Motiei M, Popovtzer R. Gold nanoparticles for in vivo cell tracking. Nanomedicine. 2014;9(13):2059–69.
Zanganeh S, Spitler R, Hutter G, Ho JQ, Pauliah M, Mahmoudi M. Tumor-associated macrophages, nanomedicine and imaging: the axis of success in the future of cancer immunotherapy. Immunotherapy. 2017;9(10):819–35.
Thanarajasingam G, Bennani-Baiti N, Thompson CA. PET-CT in staging, response evaluation, and surveillance of lymphoma. Curr Treat Options Oncol. 2016;17(5):24. https://doi.org/10.1007/s11864-016-0399-z.
Gambhir SS. Imaging of T cells in patients with recurrent glioblastoma. Transl Cancer Res. 2017;6(S7):S1291–S2.
Karls S, Shah H, Jacene H. PET/CT for lymphoma post-therapy response assessment in other lymphomas, response assessment for autologous stem cell transplant, and lymphoma follow-up. Semin Nucl Med. 2018;48(1):37–49. https://doi.org/10.1053/j.semnuclmed.2017.09.004.
Shah K. Current advances in molecular imaging of gene and cell therapy for cancer. Cancer Biol Ther. 2005;4(5):518–23. https://doi.org/10.4161/cbt.4.5.1706.
Lucignani G, Ottobrini L, Martelli C, Rescigno M, Clerici M. Molecular imaging of cell-mediated cancer immunotherapy. Trends Biotechnol. 2006;24(9):410–8. https://doi.org/10.1016/j.tibtech.2006.07.003.
Tumeh PC, Radu CG, Ribas A. PET imaging of cancer immunotherapy. J Nucl Med. 2008;49(6):865–8. https://doi.org/10.2967/jnumed.108.051342.
Lazovic J, Jensen MC, Ferkassian E, Aguilar B, Raubitschek A, Jacobs RE. Imaging immune response in vivo: cytolytic action of genetically altered T cells directed to glioblastoma multiforme. Clin Cancer Res. 2008;14(12):3832–9. https://doi.org/10.1158/1078-0432.CCR-07-5067.
Akins EJ, Dubey P. Noninvasive imaging of cell-mediated therapy for treatment of cancer. J Nucl Med. 2008;49(Suppl 2):180S–95S. https://doi.org/10.2967/jnumed.107.045971.
Ponomarev V. Nuclear imaging of cancer cell therapies. J Nucl Med. 2009;50(7):1013–6. https://doi.org/10.2967/jnumed.109.064055.
Liu G, Swierczewska M, Niu G, Zhang X, Chen X. Molecular imaging of cell-based cancer immunotherapy. Mol BioSyst. 2011;7(4):993–1003. https://doi.org/10.1039/c0mb00198h.
Kurtz DM, Gambhir SS. Tracking cellular and immune therapies in cancer. Adv Cancer Res. 2014;124:257–96.
McCracken MN, Tavaré R, Witte ON, Wu A. Advances in PET detection of the antitumor T cell response. Adv Immunol. 2016;131:187–231.
Ehlerding EB, England CG, McNeel DG, Cai W. Molecular imaging of immunotherapy targets in cancer. J Nucl Med. 2016;57(10):1487–92. https://doi.org/10.2967/jnumed.116.177493.
Haris M, Bagga P, Hariharan H, McGettigan-Croce B, Johnson LA, Reddy R. Molecular imaging biomarkers for cell-based immunotherapies. J Transl Med. 2017;15(1):140. https://doi.org/10.1186/s12967-017-1240-6.
Kurozumi S, Fujii T, Matsumoto H, Inoue K, Kurosumi M, Horiguchi J, et al. Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer. Med Mol Morphol. 2017;50(4):185–94. https://doi.org/10.1007/s00795-017-0170-y.
Ponomarev V. Advancing immune and cell-based therapies through imaging. Mol Imaging Biol. 2017;19(3):379–84. https://doi.org/10.1007/s11307-017-1069-7.
Fruhwirth GO, Kneilling M, de Vries IJM, Weigelin B, Srinivas M, Aarntzen E. The potential of in vivo imaging for optimization of molecular and cellular anti-cancer immunotherapies. Mol Imaging Biol. 2018;20(5):696–704. https://doi.org/10.1007/s11307-018-1254-3.
Marciscano AE, Thorek DLJ. Role of noninvasive molecular imaging in determining response. Adv Radiat Oncol. 2018;3(4):534–47. https://doi.org/10.1016/j.adro.2018.07.006.
Shields AF, Jacobs PM, Sznol M, Graham MM, Germain RN, Lum LG, et al. Immune modulation therapy and imaging: workshop report. J Nucl Med. 2018;59(3):410–7. https://doi.org/10.2967/jnumed.117.195610.
van der Veen EL, Bensch F, Glaudemans A, Lub-de Hooge MN, de Vries EGE. Molecular imaging to enlighten cancer immunotherapies and underlying involved processes. Cancer Treat Rev. 2018;70:232–44. https://doi.org/10.1016/j.ctrv.2018.09.007.
Wang Q, Ornstein M, Kaufman HL. Imaging the immune response to monitor tumor immunotherapy. Expert Rev Vaccines. 2009;8(10):1427–37.
Bier G, Hoffmann V, Kloth C, Othman AE, Eigentler T, Garbe C, et al. CT imaging of bone and bone marrow infiltration in malignant melanoma—challenges and limitations for clinical staging in comparison to 18FDG-PET/CT. Eur J Radiol. 2016;85(4):732–8. https://doi.org/10.1016/j.ejrad.2016.01.012.
Gholamrezanezhad A, Mirpour S, Ardekani JM, Bagheri M, Alimoghadam K, Yarmand S, et al. Cytotoxicity of 111In-oxine on mesenchymal stem cells: a time-dependent adverse effect. Nucl Med Commun. 2009;30(3):210–6.
Adonai N, Nguyen KN, Walsh J, Iyer M, Toyokuni T, Phelps ME, et al. Ex vivo cell labeling with 64Cu–pyruvaldehyde-bis (N4-methylthiosemicarbazone) for imaging cell trafficking in mice with positron-emission tomography. Proc Natl Acad Sci U S A. 2002;99(5):3030–5.
Paik J-Y, Lee K-H, Byun S-S, Choe Y, Kim B-T. Use of insulin to improve [18F] fluorodeoxyglucose labelling and retention for in vivo positron emission tomography imaging of monocyte trafficking. Nucl Med Commun. 2002;23(6):551–7.
Ridolfi R, Riccobon A, Galassi R, Giorgetti G, Petrini M, Fiammenghi L, et al. Evaluation of in vivo labelled dendritic cell migration in cancer patients. J Transl Med. 2004;2(1):27.
Meller B, Frohn C, Brand JM, Lauer I, Schelper LF, von Hof K, et al. Monitoring of a new approach of immunotherapy with allogenic (111)In-labelled NK cells in patients with renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2004;31(3):403–7. https://doi.org/10.1007/s00259-003-1398-4.
Meier R, Piert M, Piontek G, Rudelius M, Oostendorp RA, Senekowitsch-Schmidtke R, et al. Tracking of [18F] FDG-labeled natural killer cells to HER2/neu-positive tumors. Nucl Med Biol. 2008;35(5):579–88.
Melder RJ, Brownell AL, Shoup TM, Brownell GL, Jain RK. Imaging of activated natural killer cells in mice by positron emission tomography: preferential uptake in tumors. Cancer Res. 1993;53(24):5867–71.
Melder RJ, Elmaleh D, Brownell AL, Brownell GL, Jain RK. A method for labeling cells for positron emission tomography (PET) studies. J Immunol Methods. 1994;175(1):79–87.
Allan R, Sladen G, Bassingham S, Lazarus C, Clarke S, Fogelman I. Comparison of simultaneous 99m Tc-HMPAO and 111 In oxine labelled white cell scans in the assessment of inflammatory bowel disease. Eur J Nucl Med. 1993;20(3):195–200.
Blocklet D, Toungouz M, Kiss R, Lambermont M, Velu T, Duriau D, et al. 111 In-oxine and 99m Tc-HMPAO labelling of antigen-loaded dendritic cells: in vivo imaging and influence on motility and actin content. Eur J Nucl Med Mol Imaging. 2003;30(3):440–7.
Quillien V, Moisan A, Carsin A, Lesimple T, Lefeuvre C, Adamski H, et al. Biodistribution of radiolabelled human dendritic cells injected by various routes. Eur J Nucl Med Mol Imaging. 2005;32(7):731–41. https://doi.org/10.1007/s00259-005-1825-9.
Bhargava KK, Gupta RK, Nichols KJ, Palestro CJ. In vitro human leukocyte labeling with 64Cu: an intraindividual comparison with 111In-oxine and 18F-FDG. Nucl Med Biol. 2009;36(5):545–9.
de Vries EF, Roca M, Jamar F, Israel O, Signore A. Guidelines for the labelling of leucocytes with (99m)Tc-HMPAO. Inflammation/Infection Taskgroup of the European Association of Nuclear Medicine. Eur J Nucl Med Mol Imaging. 2010;37(4):842–8. https://doi.org/10.1007/s00259-010-1394-4.
Roca M, de Vries EF, Jamar F, Israel O, Signore A. Guidelines for the labelling of leucocytes with (111)In-oxine. Inflammation/Infection Taskgroup of the European Association of Nuclear Medicine. Eur J Nucl Med Mol Imaging. 2010;37(4):835–41. https://doi.org/10.1007/s00259-010-1393-5.
McAfee J, Samin A. In-111 labeled leukocytes: a review of problems in image interpretation. Radiology. 1985;155(1):221–9.
Müller C, Zielinski C, Linkesch W, Ludwig H, Sinzinger H. In vivo tracing of indium-111 oxine-labeled human peripheral blood mononuclear cells in patients with lymphatic malignancies. J Nucl Med. 1989;30(6):1005–11.
Olasz EB, Lang L, Seidel J, Green MV, Eckelman WC, Katz SI. Fluorine-18 labeled mouse bone marrow-derived dendritic cells can be detected in vivo by high resolution projection imaging. J Immunol Methods. 2002;260(1–2):137–48.
Read EJ, Keenan AM, Carter CS, Yolles PS, Davey RJ. In vivo traffic of indium-111-oxine labeled human lymphocytes collected by automated apheresis. J Nucl Med. 1990;31(6):999–1006.
Segal A, Arnot R, Thakur M, Lavender J. Indium-111-labelled leucocytes for localisation of abscesses. Lancet. 1976;308(7994):1056–8.
Thakur ML, Seifert CL, Madsen MT, McKenney SM, Desai AG, Park CH, editors. Neutrophil labeling: problems and pitfalls, Seminars in nuclear medicine. Amsterdam: Elsevier; 1984.
Hughes DK. Nuclear medicine and infection detection: the relative effectiveness of imaging with 111In-oxine-, 99mTc-HMPAO-, and 99mTc-stannous fluoride colloid-labeled leukocytes and with 67Ga-citrate. J Nucl Med Technol. 2003;31(4):196–201.
Ulker O, Genc S, Ates H, Durak H, Atabey N. 99mTc-HMPAO labelling inhibits cell motility and cell proliferation and induces apoptosis of NC-NC cells. Mutat Res. 2007;631(2):69–76. https://doi.org/10.1016/j.mrgentox.2006.12.009.
Eriksson O, Sadeghi A, Carlsson B, Eich T, Lundgren T, Nilsson B, et al. Distribution of adoptively transferred porcine T-lymphoblasts tracked by (18)F-2-fluoro-2-deoxy-D-glucose and position emission tomography. Nucl Med Biol. 2011;38(6):827–33. https://doi.org/10.1016/j.nucmedbio.2011.02.011.
Bhatnagar P, Li Z, Choi Y, Guo J, Li F, Lee DY, et al. Imaging of genetically engineered T cells by PET using gold nanoparticles complexed to Copper-64. Integr Biol (Camb). 2013;5(1):231–8. https://doi.org/10.1039/c2ib20093g.
de Vries IJ, Lesterhuis WJ, Barentsz JO, Verdijk P, van Krieken JH, Boerman OC, et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol. 2005;23(11):1407–13. https://doi.org/10.1038/nbt1154.
Srinivas M, Morel PA, Ernst LA, Laidlaw DH, Ahrens ET. Fluorine-19 MRI for visualization and quantification of cell migration in a diabetes model. Magn Reson Med. 2007;58(4):725–34.
Smirnov P, Poirier-Quinot M, Wilhelm C, Lavergne E, Ginefri JC, Combadiere B, et al. In vivo single cell detection of tumor-infiltrating lymphocytes with a clinical 1.5 Tesla MRI system. Magn Reson Med. 2008;60(6):1292–7. https://doi.org/10.1002/mrm.21812.
Srinivas M, Turner MS, Janjic JM, Morel PA, Laidlaw DH, Ahrens ET. In vivo cytometry of antigen-specific t cells using 19F MRI. Magn Reson Med. 2009;62(3):747–53.
Arbab AS, Janic B, Jafari-Khouzani K, Iskander AS, Kumar S, Varma NR, et al. Differentiation of glioma and radiation injury in rats using in vitro produce magnetically labeled cytotoxic T-cells and MRI. PLoS One. 2010;5(2):e9365. https://doi.org/10.1371/journal.pone.0009365.
Bannas P, Graumann O, Balcerak P, Peldschus K, Kaul MG, Hohenberg H, et al. Quantitative magnetic resonance imaging of enzyme activity on the cell surface: in vitro and in vivo monitoring of ADP-ribosyltransferase 2 on T cells. Mol Imaging. 2010;9(4):211–22. https://doi.org/10.2310/7290.2010.00017.
Liu L, Ye Q, Wu Y, Hsieh WY, Chen CL, Shen HH, et al. Tracking T-cells in vivo with a new nano-sized MRI contrast agent. Nanomedicine. 2012;8(8):1345–54. https://doi.org/10.1016/j.nano.2012.02.017.
Bouchlaka MN, Ludwig KD, Gordon JW, Kutz MP, Bednarz BP, Fain SB, et al. (19)F-MRI for monitoring human NK cells in vivo. Oncoimmunology. 2016;5(5):e1143996. https://doi.org/10.1080/2162402X.2016.1143996.
Gonzales C, Yoshihara HA, Dilek N, Leignadier J, Irving M, Mieville P, et al. In-vivo detection and tracking of T cells in various organs in a melanoma tumor model by 19F-fluorine MRS/MRI. PLoS One. 2016;11(10):e0164557. https://doi.org/10.1371/journal.pone.0164557.
Daldrup-Link HE, Meier R, Rudelius M, Piontek G, Piert M, Metz S, et al. In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging. Eur Radiol. 2005;15(1):4–13.
Meir R, Shamalov K, Betzer O, Motiei M, Horovitz-Fried M, Yehuda R, et al. Nanomedicine for cancer immunotherapy: tracking cancer-specific T-cells in vivo with gold nanoparticles and CT imaging. ACS Nano. 2015;9(6):6363–72.
Deguine J, Breart B, Lemaître F, Di Santo JP, Bousso P. Intravital imaging reveals distinct dynamics for natural killer and CD8+ T cells during tumor regression. Immunity. 2010;33(4):632–44.
Xu W-L, Li S-l, Ming W, Wen J-y, Jie H, Zhang H-z, et al. Tracking in vivo migration and distribution of antigen-specific cytotoxic T lymphocytes by 5,6-carboxyfluorescein diacetate succinimidyl ester staining during cancer immunotherapy. Chin Med J. 2013;126(16):3019–25.
Fisher B, Packard BS, Read EJ, Carrasquillo JA, Carter CS, Topalian SL, et al. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol. 1989;7(2):250–61.
Griffith KD, Read EJ, Carrasquillo JA, Carter CS, Yang JC, Fisher B, et al. In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. J Natl Cancer Inst. 1989;81(22):1709–17.
Pockaj BA, Sherry RM, Wei JP, Yannelli JR, Carter CS, Leitman SF, et al. Localization of 111Indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer. 1994;73(6):1731–7.
Wallace PK, Palmer LD, Perry-Lalley D, Bolton ES, Alexander RB, Horan PK, et al. Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells. Cancer Res. 1993;53(10):2358–67.
Botti C, Negri DR, Seregni E, Ramakrishna V, Arienti F, Maffioli L, et al. Comparison of three different methods for radiolabelling human activated T lymphocytes. Eur J Nucl Med. 1997;24(5):497–504.
Pittet MJ, Grimm J, Berger CR, Tamura T, Wojtkiewicz G, Nahrendorf M, et al. In vivo imaging of T cell delivery to tumors after adoptive transfer therapy. Proc Natl Acad Sci U S A. 2007;104(30):12457–61.
Agger R, Petersen MS, Petersen CC, Hansen SB, Stødkilde-Jørgensen H, Skands U, et al. T cell homing to tumors detected by 3D-coordinated positron emission tomography and magnetic resonance imaging. J Immunother. 2007;30(1):29–39.
Parente-Pereira AC, Burnet J, Ellison D, Foster J, Davies DM, van der Stegen S, et al. Trafficking of CAR-engineered human T cells following regional or systemic adoptive transfer in SCID beige mice. J Clin Immunol. 2011;31(4):710–8.
Bhatnagar P, Alauddin M, Bankson JA, Kirui D, Seifi P, Huls H, et al. Tumor lysing genetically engineered T cells loaded with multi-modal imaging agents. Sci Rep. 2014;4:4502.
Man F, Lim L, Volpe A, Gabizon A, Shmeeda H, Draper B, et al. In vivo PET tracking of (89)Zr-labeled Vgamma9Vdelta2 T cells to mouse xenograft breast tumors activated with liposomal alendronate. Mol Ther. 2019;27(1):219–29. https://doi.org/10.1016/j.ymthe.2018.10.006.
Herschman HR. PET reporter genes for noninvasive imaging of gene therapy, cell tracking and transgenic analysis. Crit Rev Oncol Hematol. 2004;51(3):191–204. https://doi.org/10.1016/j.critrevonc.2004.04.006.
Serganova I, Ponomarev V, Blasberg R. Human reporter genes: potential use in clinical studies. Nucl Med Biol. 2007;34(7):791–807. https://doi.org/10.1016/j.nucmedbio.2007.05.009.
Yaghoubi SS, Campbell DO, Radu CG, Czernin J. Positron emission tomography reporter genes and reporter probes: gene and cell therapy applications. Theranostics. 2012;2(4):374.
Brader P, Serganova I, Blasberg RG. Noninvasive molecular imaging using reporter genes. J Nucl Med. 2013;54(2):167–72. https://doi.org/10.2967/jnumed.111.099788.
Herschman HR. Noninvasive imaging of reporter gene expression in living subjects. Adv Cancer Res. 2004;92:30–80.
Gambhir SS, Bauer E, Black ME, Liang Q, Kokoris MS, Barrio JR, et al. A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography. Proc Natl Acad Sci U S A. 2000;97(6):2785–90.
Doubrovin M, Ponomarev V, Beresten T, Balatoni J, Bornmann W, Finn R, et al. Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo. Proc Natl Acad Sci U S A. 2001;98(16):9300–5.
Jacobs A, Tjuvajev JG, Dubrovin M, Akhurst T, Balatoni J, Beattie B, et al. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. Cancer Res. 2001;61(7):2983–95.
Liang Q, Gotts J, Satyamurthy N, Barrio J, Phelps ME, Gambhir SS, et al. Noninvasive, repetitive, quantitative measurement of gene expression from a bicistronic message by positron emission tomography, following gene transfer with adenovirus. Mol Ther. 2002;6(1):73–82.
Tjuvajev JG, Doubrovin M, Akhurst T, Cai S, Balatoni J, Alauddin MM, et al. Comparison of radiolabeled nucleoside probes (FIAU, FHBG, and FHPG) for PET imaging of HSV1-tk gene expression. J Nucl Med. 2002;43(8):1072–83.
Min JJ, Iyer M, Gambhir SS. Comparison of [18F]FHBG and [14C]FIAU for imaging of HSV1-tk reporter gene expression: adenoviral infection vs stable transfection. Eur J Nucl Med Mol Imaging. 2003;30(11):1547–60. https://doi.org/10.1007/s00259-003-1238-6.
Ponomarev V, Doubrovin M, Serganova I, Vider J, Shavrin A, Beresten T, et al. A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging. Eur J Nucl Med Mol Imaging. 2004;31(5):740–51.
Ponomarev V, Doubrovin M, Shavrin A, Serganova I, Beresten T, Ageyeva L, et al. A human-derived reporter gene for noninvasive imaging in humans: mitochondrial thymidine kinase type 2. J Nucl Med. 2007;48(5):819–26. https://doi.org/10.2967/jnumed.106.036962.
Niu G, Gaut AW, Ponto LLB, Hichwa RD, Madsen MT, Graham MM, et al. Multimodality noninvasive imaging of gene transfer using the human sodium iodide symporter. J Nucl Med. 2004;45(3):445–9.
Ray P, De A, Min J-J, Tsien RY, Gambhir SS. Imaging tri-fusion multimodality reporter gene expression in living subjects. Cancer Res. 2004;64(4):1323–30.
Chin FT, Namavari M, Levi J, Subbarayan M, Ray P, Chen X, et al. Semiautomated radiosynthesis and biological evaluation of [18F]FEAU: a novel PET imaging agent for HSV1-tk/sr39tk reporter gene expression. Mol Imaging Biol. 2008;10(2):82–91. https://doi.org/10.1007/s11307-007-0122-3.
Cho SY, Ravasi L, Szajek LP, Seidel J, Green MV, Fine HA, et al. Evaluation of 76Br-FBAU as a PET reporter probe for HSV1-tk gene expression imaging using mouse models of human glioma. J Nucl Med. 2005;46(11):1923–30.
Yaghoubi SS, Barrio JR, Namavari M, Satyamurthy N, Phelps ME, Herschman HR, et al. Imaging progress of herpes simplex virus type 1 thymidine kinase suicide gene therapy in living subjects with positron emission tomography. Cancer Gene Ther. 2005;12(3):329.
Soghomonyan S, Hajitou A, Rangel R, Trepel M, Pasqualini R, Arap W, et al. Molecular PET imaging of HSV1-tk reporter gene expression using [18F]FEAU. Nat Protoc. 2007;2(2):416–23. https://doi.org/10.1038/nprot.2007.49.
Barton KN, Stricker H, Brown SL, Elshaikh M, Aref I, Lu M, et al. Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate. Mol Ther. 2008;16(10):1761–9. https://doi.org/10.1038/mt.2008.172.
Miyagawa T, Gogiberidze G, Serganova I, Cai S, Balatoni JA, Thaler HT, et al. Imaging of HSV-tk Reporter gene expression: comparison between [18F]FEAU, [18F]FFEAU, and other imaging probes. J Nucl Med. 2008;49(4):637–48. https://doi.org/10.2967/jnumed.107.046227.
Chan P-C, Wu C-Y, Chang W-Y, Chang W-T, Alauddin M, Liu R-S, et al. Evaluation of F-18-labeled 5-iodocytidine (18F-FIAC) as a new potential positron emission tomography probe for herpes simplex virus type 1 thymidine kinase imaging. Nucl Med Biol. 2011;38(7):987–95.
Niers JM, Chen JW, Lewandrowski G, Kerami M, Garanger E, Wojtkiewicz G, et al. Single reporter for targeted multimodal in vivo imaging. J Am Chem Soc. 2012;134(11):5149–56. https://doi.org/10.1021/ja209868g.
Lee WW, Moon DH, Park SY, Jin J, Kim SJ, Lee H. Imaging of adenovirus-mediated expression of human sodium iodide symporter gene by 99mTcO4 scintigraphy in mice. Nucl Med Biol. 2004;31(1):31–40.
Bettegowda C, Foss CA, Cheong I, Wang Y, Diaz L, Agrawal N, et al. Imaging bacterial infections with radiolabeled 1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl)-5-iodouracil. Proc Natl Acad Sci U S A. 2005;102(4):1145–50.
Sun H, Mangner TJ, Collins JM, Muzik O, Douglas K, Shields AF. Imaging DNA synthesis in vivo with 18F-FMAU and PET. J Nucl Med. 2005;46(2):292–6.
Le LQ, Kabarowski JH, Wong S, Nguyen K, Gambhir SS, Witte ON. Positron emission tomography imaging analysis of G2A as a negative modifier of lymphoid leukemogenesis initiated by the BCR-ABL oncogene. Cancer Cell. 2002;1(4):381–91.
Park J-J, Lee T-S, Son J-J, Chun K-S, Song I-H, Park Y-S, et al. Comparison of cell-labeling methods with 124I-FIAU and 64Cu-PTSM for cell tracking using chronic myelogenous leukemia cells expressing HSV1-tk and firefly luciferase. Cancer Biother Radiopharm. 2012;27(10):719–28.
Mayer-Kuckuk P, Doubrovin M, Bidaut L, Budak-Alpdogan T, Cai S, Hubbard V, et al. Molecular imaging reveals skeletal engraftment sites of transplanted bone marrow cells. Cell Transplant. 2006;15(1):75–82.
McCracken MN, Gschweng EH, Nair-Gill E, McLaughlin J, Cooper AR, Riedinger M, et al. Long-term in vivo monitoring of mouse and human hematopoietic stem cell engraftment with a human positron emission tomography reporter gene. Proc Natl Acad Sci U S A. 2013;110(5):1857–62. https://doi.org/10.1073/pnas.1221840110.
Lee HW, Yoon SY, Singh TD, Choi YJ, Lee HJ, Park JY, et al. Tracking of dendritic cell migration into lymph nodes using molecular imaging with sodium iodide symporter and enhanced firefly luciferase genes. Sci Rep. 2015;5:9865. https://doi.org/10.1038/srep09865.
Lee SB, Lee HW, Lee H, Jeon YH, Lee SW, Ahn BC, et al. Tracking dendritic cell migration into lymph nodes by using a novel PET probe (18)F-tetrafluoroborate for sodium/iodide symporter. EJNMMI Res. 2017;7(1):32. https://doi.org/10.1186/s13550-017-0280-5.
Ponomarev V, Doubrovin M, Lyddane C, Beresten T, Balatoni J, Bornman W, et al. Imaging TCR-dependent NFAT-mediated T-cell activation with positron emission tomography in vivo. Neoplasia (New York, NY). 2001;3(6):480.
Koehne G, Doubrovin M, Doubrovina E, Zanzonico P, Gallardo HF, Ivanova A, et al. Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes. Nat Biotechnol. 2003;21(4):405.
Zanzonico P, Koehne G, Gallardo HF, Doubrovin M, Doubrovina E, Finn R, et al. [131I]FIAU labeling of genetically transduced, tumor-reactive lymphocytes: cell-level dosimetry and dose-dependent toxicity. Eur J Nucl Med Mol Imaging. 2006;33(9):988–97. https://doi.org/10.1007/s00259-005-0057-3.
Dubey P, Su H, Adonai N, Du S, Rosato A, Braun J, et al. Quantitative imaging of the T cell antitumor response by positron-emission tomography. Proc Natl Acad Sci U S A. 2003;100(3):1232–7.
Su H, Forbes A, Gambhir SS, Braun J. Quantitation of cell number by a positron emission tomography reporter gene strategy. Mol Imaging Biol. 2004;6(3):139–48.
Shu CJ, Guo S, Kim YJ, Shelly SM, Nijagal A, Ray P, et al. Visualization of a primary anti-tumor immune response by positron emission tomography. Proc Natl Acad Sci U S A. 2005;102(48):17412–7.
Shu CJ, Radu CG, Shelly SM, Vo DD, Prins R, Ribas A, et al. Quantitative PET reporter gene imaging of CD8+ T cells specific for a melanoma-expressed self-antigen. Int Immunol. 2009;21(2):155–65. https://doi.org/10.1093/intimm/dxn133.
Su H, Chang DS, Gambhir SS, Braun J. Monitoring the antitumor response of naive and memory CD8 T cells in RAG1−/− mice by positron-emission tomography. J Immunol. 2006;176(7):4459–67. https://doi.org/10.4049/jimmunol.176.7.4459.
Yaghoubi SS, Jensen MC, Satyamurthy N, Budhiraja S, Paik D, Czernin J, et al. Noninvasive detection of therapeutic cytolytic T cells with 18 F–FHBG PET in a patient with glioma. Nat Rev Clin Oncol. 2009;6(1):53.
Keu KV, Witney TH, Yaghoubi S, Rosenberg J, Kurien A, Magnusson R, et al. Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma. Sci Transl Med. 2017;9(373):eaag2196.
Dobrenkov K, Olszewska M, Likar Y, Shenker L, Gunset G, Cai S, et al. Monitoring the efficacy of adoptively transferred prostate cancer-targeted human T lymphocytes with PET and bioluminescence imaging. J Nucl Med. 2008;49(7):1162–70. https://doi.org/10.2967/jnumed.107.047324.
Dotti G, Tian M, Savoldo B, Najjar A, Cooper LJ, Jackson J, et al. Repetitive noninvasive monitoring of HSV1-tk-expressing T cells intravenously infused into nonhuman primates using positron emission tomography and computed tomography with 18F-FEAU. Mol Imaging. 2009;8(4):230–7.
Najjar AM, Manuri PR, Olivares S, Flores L II, Mi T, Huls H, et al. Imaging of sleeping beauty-modified CD19-specific T cells expressing HSV1-thymidine kinase by positron emission tomography. Mol Imaging Biol. 2016;18(6):838–48. https://doi.org/10.1007/s11307-016-0971-8.
Vedvyas Y, Shevlin E, Zaman M, Min IM, Amor-Coarasa A, Park S, et al. Longitudinal PET imaging demonstrates biphasic CAR T cell responses in survivors. JCI Insight. 2016;1(19):e90064. https://doi.org/10.1172/jci.insight.90064.
Park S, Shevlin E, Vedvyas Y, Zaman M, Park S, Hsu YS, et al. Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity. Sci Rep. 2017;7(1):14366. https://doi.org/10.1038/s41598-017-14749-3.
Mall S, Yusufi N, Wagner R, Klar R, Bianchi H, Steiger K, et al. Immuno-PET imaging of engineered human T cells in tumors. Cancer Res. 2016;76(14):4113–23. https://doi.org/10.1158/0008-5472.CAN-15-2784.
Yusufi N, Mall S, Bianchi HO, Steiger K, Reder S, Klar R, et al. In-depth characterization of a TCR-specific tracer for sensitive detection of tumor-directed transgenic T cells by immuno-PET. Theranostics. 2017;7(9):2402–16. https://doi.org/10.7150/thno.17994.
Yusufi N, Mall S, de Oliveira Bianchi H, Steiger K, Reder S, Klar R, et al. In-depth characterization of a TCR-specific tracer for sensitive detection of tumor-directed transgenic T cells by immuno-PET. Theranostics. 2017;7(9):2402.
Krebs S, Ahad A, Carter LM, Eyquem J, Brand C, Bell M, et al. Antibody with infinite affinity for in vivo tracking of genetically engineered lymphocytes. J Nucl Med. 2018;59(12):1894–900. https://doi.org/10.2967/jnumed.118.208041.
Bruno R, Giannasio P, Ronga G, Baudin E, Travagli J, Russo D, et al. Sodium iodide symporter expression and radioiodine distribution in extrathyroidal tissues. J Endocrinol Investig. 2004;27(11):1010–4.
Sharp SE, Trout AT, Weiss BD, Gelfand MJ. MIBG in neuroblastoma diagnostic imaging and therapy. Radiographics. 2016;36(1):258–78.
Moroz MA, Serganova I, Zanzonico P, Ageyeva L, Beresten T, Dyomina E, et al. Imaging hNET reporter gene expression with 124I-MIBG. J Nucl Med. 2007;48(5):827–36.
Doubrovin MM, Doubrovina ES, Zanzonico P, Sadelain M, Larson SM, O’Reilly RJ. In vivo imaging and quantitation of adoptively transferred human antigen-specific T cells transduced to express a human norepinephrine transporter gene. Cancer Res. 2007;67(24):11959–69. https://doi.org/10.1158/0008-5472.CAN-07-1250.
Radu CG, Shu CJ, Nair-Gill E, Shelly SM, Barrio JR, Satyamurthy N, et al. Molecular imaging of lymphoid organs and immune activation by positron emission tomography with a new [18F]-labeled 2′-deoxycytidine analog. Nat Med. 2008;14(7):783–8. https://doi.org/10.1038/nm1724.
Schwarzenberg J, Radu CG, Benz M, Fueger B, Tran AQ, Phelps ME, et al. Human biodistribution and radiation dosimetry of novel PET probes targeting the deoxyribonucleoside salvage pathway. Eur J Nucl Med Mol Imaging. 2011;38(4):711–21. https://doi.org/10.1007/s00259-010-1666-z.
Antonios JP, Soto H, Everson RG, Moughon DL, Wang AC, Orpilla J, et al. Detection of immune responses after immunotherapy in glioblastoma using PET and MRI. Proc Natl Acad Sci U S A. 2017;114(38):10220–5. https://doi.org/10.1073/pnas.1706689114.
Shu CJ, Campbell DO, Lee JT, Tran AQ, Wengrod JC, Witte ON, et al. Novel PET probes specific for deoxycytidine kinase. J Nucl Med. 2010;51(7):1092–8. https://doi.org/10.2967/jnumed.109.073361.
Kim W, Le TM, Wei L, Poddar S, Bazzy J, Wang X, et al. [18F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activity. Proc Natl Acad Sci U S A. 2016;113(15):4027–32. https://doi.org/10.1073/pnas.1524212113.
Franc BL, Goth S, MacKenzie J, Li X, Blecha J, Lam T, et al. In vivo PET imaging of the activated immune environment in a small animal model of inflammatory arthritis. Mol Imaging. 2017;16:1536012117712638. https://doi.org/10.1177/1536012117712638.
Namavari M, Chang YF, Kusler B, Yaghoubi S, Mitchell BS, Gambhir SS. Synthesis of 2′-deoxy-2′-[18F]fluoro-9-beta-D-arabinofuranosylguanine: a novel agent for imaging T-cell activation with PET. Mol Imaging Biol. 2011;13(5):812–8. https://doi.org/10.1007/s11307-010-0414-x.
Levi J, Lam T, Goth SR, Yaghoubi S, Bates J, Ren G, et al. Imaging of activated T cells as an early predictor of immune response to anti-PD-1 therapy. Cancer Res. 2019;79(13):3455–65.
McCracken MN, Vatakis DN, Dixit D, McLaughlin J, Zack JA, Witte ON. Noninvasive detection of tumor-infiltrating T cells by PET reporter imaging. J Clin Invest. 2015;125(5):1815–26.
Ribas A, Benz MR, Allen-Auerbach MS, Radu C, Chmielowski B, Seja E, et al. Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab. J Nucl Med. 2010;51(3):340–6. https://doi.org/10.2967/jnumed.109.070946.
Aarntzen EH, Srinivas M, De Wilt JH, Jacobs JF, Lesterhuis WJ, Windhorst AD, et al. Early identification of antigen-specific immune responses in vivo by [18F]-labeled 3′-fluoro-3′-deoxy-thymidine ([18F] FLT) PET imaging. Proc Natl Acad Sci U S A. 2011;108(45):18396–9.
Scarpelli M, Zahm C, Perlman S, McNeel DG, Jeraj R, Liu G. FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab. J Immunother Cancer. 2019;7(1):23.
Abbs IC, Pratt JR, Dallman MJ, Sacks SH. Analysis of activated T cell infiltrates in rat renal allografts by gamma camera imaging after injection of 123iodine-interleukin 2. Transpl Immunol. 1993;1(1):45–51.
Annovazzi A, Biancone L, Caviglia R, Chianelli M, Capriotti G, Mather SJ, et al. 99mTc-interleukin-2 and (99m)Tc-HMPAO granulocyte scintigraphy in patients with inactive Crohn’s disease. Eur J Nucl Med Mol Imaging. 2003;30(3):374–82. https://doi.org/10.1007/s00259-002-1069-x.
Annovazzi A, D’Alessandria C, Bonanno E, Mather SJ, Cornelissen B, van de Wiele C, et al. Synthesis of 99mTc-HYNIC-interleukin-12, a new specific radiopharmaceutical for imaging T lymphocytes. Eur J Nucl Med Mol Imaging. 2006;33(4):474–82. https://doi.org/10.1007/s00259-005-0001-6.
Gross MD, Shapiro B, Fig LM, Steventon R, Skinner RW, Hay RV. Imaging of human infection with 131I-labeled recombinant human interleukin-8. J Nucl Med. 2001;42(11):1656–9.
Glaudemans AW, Bonanno E, Galli F, Zeebregts CJ, de Vries EF, Koole M, et al. In vivo and in vitro evidence that (9)(9)mTc-HYNIC-interleukin-2 is able to detect T lymphocytes in vulnerable atherosclerotic plaques of the carotid artery. Eur J Nucl Med Mol Imaging. 2014;41(9):1710–9. https://doi.org/10.1007/s00259-014-2764-0.
Di Gialleonardo V, Signore A, Willemsen AT, Sijbesma JW, Dierckx RA, de Vries EF. Pharmacokinetic modelling of N-(4-[(18)F]fluorobenzoyl)interleukin-2 binding to activated lymphocytes in an xenograft model of inflammation. Eur J Nucl Med Mol Imaging. 2012;39(10):1551–60. https://doi.org/10.1007/s00259-012-2176-y.
Di Gialleonardo V, Signore A, Glaudemans AW, Dierckx RA, De Vries EF. N-(4-18F-fluorobenzoyl)interleukin-2 for PET of human-activated T lymphocytes. J Nucl Med. 2012;53(5):679–86. https://doi.org/10.2967/jnumed.111.091306.
Signore A, Annovazzi A, Barone R, Bonanno E, D’Alessandria C, Chianelli M, et al. 99mTc-interleukin-2 scintigraphy as a potential tool for evaluating tumor-infiltrating lymphocytes in melanoma lesions: a validation study. J Nucl Med. 2004;45(10):1647–52.
Loose D, Signore A, Staelens L, Bulcke KV, Vermeersch H, Dierckx RA, et al. (123)I-Interleukin-2 uptake in squamous cell carcinoma of the head and neck carcinoma. Eur J Nucl Med Mol Imaging. 2008;35(2):281–6. https://doi.org/10.1007/s00259-007-0609-9.
Markovic SN, Galli F, Suman VJ, Nevala WK, Paulsen AM, Hung JC, et al. Non-invasive visualization of tumor infiltrating lymphocytes in patients with metastatic melanoma undergoing immune checkpoint inhibitor therapy: a pilot study. Oncotarget. 2018;9(54):30268.
Hartimath SV, Manuelli V, Zijlma R, Signore A, Nayak TK, Freimoser-Grundschober A, et al. Pharmacokinetic properties of radiolabeled mutant Interleukin-2v: a PET imaging study. Oncotarget. 2018;9(6):7162.
Klein C, Waldhauer I, Nicolini VG, Freimoser-Grundschober A, Nayak T, Vugts DJ, et al. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. Oncoimmunology. 2017;6(3):e1277306. https://doi.org/10.1080/2162402X.2016.1277306.
Walther M, Gebhardt P, Grosse-Gehling P, Wurbach L, Irmler I, Preusche S, et al. Implementation of 89Zr production and in vivo imaging of B-cells in mice with 89Zr-labeled anti-B-cell antibodies by small animal PET/CT. Appl Radiat Isot. 2011;69(6):852–7. https://doi.org/10.1016/j.apradiso.2011.02.040.
Olafsen T, Sirk SJ, Betting DJ, Kenanova VE, Bauer KB, Ladno W, et al. ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies). Protein Eng Des Sel. 2010;23(4):243–9.
Olafsen T, Betting D, Kenanova VE, Salazar FB, Clarke P, Said J, et al. Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas. J Nucl Med. 2009;50(9):1500–8.
Natarajan A, Gambhir SS. Radiation dosimetry study of [(89)Zr]rituximab tracer for clinical translation of B cell NHL imaging using positron emission tomography. Mol Imaging Biol. 2015;17(4):539–47. https://doi.org/10.1007/s11307-014-0810-8.
Natarajan A, Habte F, Gambhir SS. Development of a novel long-lived immunoPET tracer for monitoring lymphoma therapy in a humanized transgenic mouse model. Bioconjug Chem. 2012;23(6):1221–9. https://doi.org/10.1021/bc300039r.
Natarajan A, Hackel BJ, Gambhir SS. A novel engineered anti-CD20 tracer enables early time PET imaging in a humanized transgenic mouse model of B-cell non-Hodgkins lymphoma. Clin Cancer Res. 2013;19(24):6820–9.
Zettlitz KA, Tavaré R, Knowles SM, Steward KK, Timmerman JM, Wu AM. ImmunoPET of malignant and normal B cells with 89Zr-and 124I-labeled obinutuzumab antibody fragments reveals differential CD20 internalization in vivo. Clin Cancer Res. 2017;23(23):7242–52.
Rashidian M, Keliher EJ, Bilate AM, Duarte JN, Wojtkiewicz GR, Jacobsen JT, et al. Noninvasive imaging of immune responses. Proc Natl Acad Sci U S A. 2015;112(19):6146–51.
Movahedi K, Schoonooghe S, Laoui D, Houbracken I, Waelput W, Breckpot K, et al. Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages. Cancer Res. 2012;72(16):4165–77. https://doi.org/10.1158/0008-5472.CAN-11-2994.
Blykers A, Schoonooghe S, Xavier C, D’Hoe K, Laoui D, D’Huyvetter M, et al. PET imaging of macrophage mannose receptor-expressing macrophages in tumor stroma using 18F-radiolabeled camelid single-domain antibody fragments. J Nucl Med. 2015;56(8):1265–71. https://doi.org/10.2967/jnumed.115.156828.
Seo JH, Jeon YH, Lee YJ, Yoon GS, Won DI, Ha JH, et al. Trafficking macrophage migration using reporter gene imaging with human sodium iodide symporter in animal models of inflammation. J Nucl Med. 2010;51(10):1637–43. https://doi.org/10.2967/jnumed.110.077891.
Freise AC, Zettlitz KA, Salazar FB, Lu X, Tavare R, Wu AM. ImmunoPET imaging of murine CD4(+) T cells using anti-CD4 Cys-Diabody: effects of protein dose on T cell function and imaging. Mol Imaging Biol. 2017;19(4):599–609. https://doi.org/10.1007/s11307-016-1032-z.
Tavare R, McCracken MN, Zettlitz KA, Knowles SM, Salazar FB, Olafsen T, et al. Engineered antibody fragments for immuno-PET imaging of endogenous CD8+ T cells in vivo. Proc Natl Acad Sci U S A. 2014;111(3):1108–13. https://doi.org/10.1073/pnas.1316922111.
Kanwar B, Gao DW, Hwang AB, Grenert JP, Williams SP, Franc B, et al. In vivo imaging of mucosal CD4+ T cells using single photon emission computed tomography in a murine model of colitis. J Immunol Methods. 2008;329(1–2):21–30. https://doi.org/10.1016/j.jim.2007.09.008.
Freise AC, Zettlitz KA, Salazar FB, Tavare R, Tsai WK, Chatziioannou AF, et al. Immuno-PET in inflammatory bowel disease: imaging CD4-positive T cells in a murine model of colitis. J Nucl Med. 2018;59(6):980–5. https://doi.org/10.2967/jnumed.117.199075.
Di Mascio M, Srinivasula S, Kim I, Duralde G, St Claire A, DeGrange P, et al. Total body CD4+ T cell dynamics in treated and untreated SIV infection revealed by in vivo imaging. JCI Insight. 2018;3(13):e97880. https://doi.org/10.1172/jci.insight.97880.
Ronald JA, Kim BS, Gowrishankar G, Namavari M, Alam IS, D’Souza A, et al. A PET imaging strategy to visualize activated T cells in acute graft-versus-host disease elicited by allogenic hematopoietic cell transplant. Cancer Res. 2017;77(11):2893–902. https://doi.org/10.1158/0008-5472.CAN-16-2953.
Tavare R, McCracken MN, Zettlitz KA, Salazar FB, Olafsen T, Witte ON, et al. Immuno-PET of murine T cell reconstitution postadoptive stem cell transplantation using anti-CD4 and anti-CD8 Cys-Diabodies. J Nucl Med. 2015;56(8):1258–64. https://doi.org/10.2967/jnumed.114.153338.
Heskamp S, Hobo W, Molkenboer-Kuenen JD, Olive D, Oyen WJ, Dolstra H, et al. Noninvasive imaging of tumor PD-L1 expression using radiolabeled anti-PD-L1 antibodies. Cancer Res. 2015;75(14):2928–36. https://doi.org/10.1158/0008-5472.CAN-14-3477.
Maute RL, Gordon SR, Mayer AT, McCracken MN, Natarajan A, Ring NG, et al. Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. Proc Natl Acad Sci U S A. 2015;112(47):E6506–14. https://doi.org/10.1073/pnas.1519623112.
Chatterjee S, Lesniak WG, Gabrielson M, Lisok A, Wharram B, Sysa-Shah P, et al. A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors. Oncotarget. 2016;7(9):10215.
Lesniak WG, Chatterjee S, Gabrielson M, Lisok A, Wharram B, Pomper MG, et al. PD-L1 detection in tumors using [(64)Cu]Atezolizumab with PET. Bioconjug Chem. 2016;27(9):2103–10. https://doi.org/10.1021/acs.bioconjchem.6b00348.
Josefsson A, Nedrow JR, Park S, Banerjee SR, Rittenbach A, Jammes F, et al. Imaging, biodistribution, and dosimetry of radionuclide-labeled PD-L1 antibody in an immunocompetent mouse model of breast cancer. Cancer Res. 2016;76(2):472–9. https://doi.org/10.1158/0008-5472.CAN-15-2141.
Mayer AT, Natarajan A, Gordon SR, Maute RL, McCracken MN, Ring AM, et al. Practical immuno-PET radiotracer design considerations for human immune checkpoint imaging. J Nucl Med. 2017;58(4):538–46. https://doi.org/10.2967/jnumed.116.177659.
Nedrow JR, Josefsson A, Park S, Ranka S, Roy S, Sgouros G. Imaging of programmed cell death ligand 1: impact of protein concentration on distribution of anti-PD-L1 SPECT agents in an immunocompetent murine model of melanoma. J Nucl Med. 2017;58(10):1560–6. https://doi.org/10.2967/jnumed.117.193268.
Chatterjee S, Lesniak WG, Nimmagadda S. Noninvasive imaging of immune checkpoint ligand PD-L1 in tumors and metastases for guiding immunotherapy. Mol Imaging. 2017;16:1536012117718459.
Kikuchi M, Clump DA, Srivastava RM, Sun L, Zeng D, Diaz-Perez JA, et al. Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma. Oncoimmunology. 2017;6(7):e1329071.
Truillet C, Oh HLJ, Yeo SP, Lee CY, Huynh LT, Wei J, et al. Imaging PD-L1 expression with ImmunoPET. Bioconjug Chem. 2018;29(1):96–103. https://doi.org/10.1021/acs.bioconjchem.7b00631.
Ehlerding EB, England CG, Majewski RL, Valdovinos HF, Jiang D, Liu G, et al. ImmunoPET imaging of CTLA-4 expression in mouse models of non-small cell lung cancer. Mol Pharm. 2017;14(5):1782–9. https://doi.org/10.1021/acs.molpharmaceut.7b00056.
Natarajan A, Mayer AT, Xu L, Reeves RE, Gano J, Gambhir SS. Novel radiotracer for ImmunoPET imaging of PD-1 checkpoint expression on tumor infiltrating lymphocytes. Bioconjug Chem. 2015;26(10):2062–9. https://doi.org/10.1021/acs.bioconjchem.5b00318.
Hettich M, Braun F, Bartholoma MD, Schirmbeck R, Niedermann G. High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers. Theranostics. 2016;6(10):1629–40. https://doi.org/10.7150/thno.15253.
England CG, Ehlerding EB, Hernandez R, Rekoske BT, Graves SA, Sun H, et al. Preclinical pharmacokinetics and biodistribution studies of 89Zr-labeled pembrolizumab. J Nucl Med. 2017;58(1):162–8. https://doi.org/10.2967/jnumed.116.177857.
Natarajan A, Mayer AT, Reeves RE, Nagamine CM, Gambhir SS. Development of novel ImmunoPET tracers to image human PD-1 checkpoint expression on tumor-infiltrating lymphocytes in a humanized mouse model. Mol Imaging Biol. 2017;19(6):903–14. https://doi.org/10.1007/s11307-017-1060-3.
Natarajan A, Patel CB, Habte F, Gambhir SS. Dosimetry prediction for clinical translation of (64)Cu-pembrolizumab ImmunoPET targeting human PD-1 expression. Sci Rep. 2018;8(1):633. https://doi.org/10.1038/s41598-017-19123-x.
England CG, Jiang D, Ehlerding EB, Rekoske BT, Ellison PA, Hernandez R, et al. (89)Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer. Eur J Nucl Med Mol Imaging. 2018;45(1):110–20. https://doi.org/10.1007/s00259-017-3803-4.
Du Y, Liang X, Li Y, Sun T, Jin Z, Xue H, et al. Nuclear and fluorescent labeled PD-1-liposome-DOX-(64)Cu/IRDye800CW allows improved breast tumor targeted imaging and therapy. Mol Pharm. 2017;14(11):3978–86. https://doi.org/10.1021/acs.molpharmaceut.7b00649.
Higashikawa K, Yagi K, Watanabe K, Kamino S, Ueda M, Hiromura M, et al. 64Cu-DOTA-anti-CTLA-4 mAb enabled PET visualization of CTLA-4 on the T-cell infiltrating tumor tissues. PLoS One. 2014;9(11):e109866. https://doi.org/10.1371/journal.pone.0109866.
Higashikawa K, Yagi K, Watanabe K, Kamino S, Ueda M, Hiromura M, et al. 64 Cu-DOTA-anti-CTLA-4 mAb enabled PET visualization of CTLA-4 on the T-cell infiltrating tumor tissues. PLoS One. 2014;9(11):e109866.
Malviya G, D’Alessandria C, Bonanno E, Vexler V, Massari R, Trotta C, et al. Radiolabeled humanized anti-CD3 monoclonal antibody visilizumab for imaging human T-lymphocytes. J Nucl Med. 2009;50(10):1683–91.
Larimer BM, Wehrenberg-Klee E, Caraballo A, Mahmood U. Quantitative CD3 PET imaging predicts tumor growth response to anti-CTLA-4 therapy. J Nucl Med. 2016;57(10):1607–11. https://doi.org/10.2967/jnumed.116.173930.
Beckford Vera DR, Smith CC, Bixby LM, Glatt DM, Dunn SS, Saito R, et al. Immuno-PET imaging of tumor-infiltrating lymphocytes using zirconium-89 radiolabeled anti-CD3 antibody in immune-competent mice bearing syngeneic tumors. PLoS One. 2018;13(3):e0193832. https://doi.org/10.1371/journal.pone.0193832.
Tavare R, Escuin-Ordinas H, Mok S, McCracken MN, Zettlitz KA, Salazar FB, et al. An effective Immuno-PET imaging method to monitor CD8-dependent responses to immunotherapy. Cancer Res. 2016;76(1):73–82. https://doi.org/10.1158/0008-5472.CAN-15-1707.
Rashidian M, Ingram JR, Dougan M, Dongre A, Whang KA, LeGall C, et al. Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells. J Exp Med. 2017;214(8):2243–55. https://doi.org/10.1084/jem.20161950.
Alam IS, Mayer AT, Sagiv-Barfi I, Wang K, Vermesh O, Czerwinski DK, et al. Imaging activated T cells predicts response to cancer vaccines. J Clin Investig. 2018;128(6):2569–80.
Matsui K, Wang Z, McCarthy TJ, Allen PM, Reichert DE. Quantitation and visualization of tumor-specific T cells in the secondary lymphoid organs during and after tumor elimination by PET. Nucl Med Biol. 2004;31(8):1021–31. https://doi.org/10.1016/j.nucmedbio.2004.06.002.
Larimer BM, Wehrenberg-Klee E, Dubois F, Mehta A, Kalomeris T, Flaherty K, et al. Granzyme B PET imaging as a predictive biomarker of immunotherapy response. Cancer Res. 2017;77(9):2318–27. https://doi.org/10.1158/0008-5472.CAN-16-3346.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Ethics declarations
The authors report no conflict of interest with the material presented in this study. Dr. François Bénard is co-founder, director, and shareholder of Alpha-9 Theranostics, a radiopharmaceutical company. No other potential conflicts of interest relevant to this article exist.
Rights and permissions
Copyright information
© 2022 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Roxin, Á., Bénard, F. (2022). Radioimaging of Activated T Cells in Preclinical and Clinical Cancer Investigations. In: Harsini, S., Alavi, A., Rezaei, N. (eds) Nuclear Medicine and Immunology. Springer, Cham. https://doi.org/10.1007/978-3-030-81261-4_3
Download citation
DOI: https://doi.org/10.1007/978-3-030-81261-4_3
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-81260-7
Online ISBN: 978-3-030-81261-4
eBook Packages: MedicineMedicine (R0)